Therefore, if in a particular patient with AD the plasma level of TGF-β is reduced, then its levels should be raised [72], which may be accomplished by the administration of fluoxetine, which approximately doubles the levels [73]. This evidence concerns the gene TGFB1 and Alzheimer disease.